This document summarizes a report from Aarkstore Enterprise that provides an analysis of over 500 sexual health partnering deals and agreements between leading healthcare companies. The report details how and why companies enter these partnerships, which mostly involve collaborative R&D and commercialization of discoveries at early development stages. Understanding the flexibility in negotiated deal terms provides insight for prospective partners into what can be expected during negotiations, especially regarding payment clauses and how payments are triggered.
Choosing Initial and Expansion States for Your Telehealth Practice – Essentia...Epstein Becker Green
Epstein Becker Green Webinar with Attorney Bradley S. Davidsen - Telehealth Essentials for Start-Ups Crash Course Webinar Series - July 17, 2018.
Discussion Points:
* Which model makes the most sense for my telehealth start-up to begin offering telehealth services: a one-state, surrounding states/regional, select states, or national model?
* If I want to expand slowly/regionally, what factors should I consider in determining which states should be part of my initial expansion?
* If I want to expand into a national model, what factors are important in choosing the first state(s) in which to practice? Which states should I expand into next? Why not start in all 50 states?
Take a coffee break every Tuesday in July at 2 p.m. ET to join us for a 15-minute webinar covering telehealth and telemedicine issues! https://www.ebglaw.com/crashjuly
https://www.ebglaw.com/events/five-factors-to-consider-when-choosing-initial-and-expansion-states-for-your-telehealth-practice-telehealth-essentials-for-start-ups-crash-course-webinar-series/
#telehealth #telemedicine #startups #healthcare #healthIT #physicians #hospitals #pharma #prescribing #healthtech #healthlaw
Choosing Initial and Expansion States for Your Telehealth Practice – Essentia...Epstein Becker Green
Epstein Becker Green Webinar with Attorney Bradley S. Davidsen - Telehealth Essentials for Start-Ups Crash Course Webinar Series - July 17, 2018.
Discussion Points:
* Which model makes the most sense for my telehealth start-up to begin offering telehealth services: a one-state, surrounding states/regional, select states, or national model?
* If I want to expand slowly/regionally, what factors should I consider in determining which states should be part of my initial expansion?
* If I want to expand into a national model, what factors are important in choosing the first state(s) in which to practice? Which states should I expand into next? Why not start in all 50 states?
Take a coffee break every Tuesday in July at 2 p.m. ET to join us for a 15-minute webinar covering telehealth and telemedicine issues! https://www.ebglaw.com/crashjuly
https://www.ebglaw.com/events/five-factors-to-consider-when-choosing-initial-and-expansion-states-for-your-telehealth-practice-telehealth-essentials-for-start-ups-crash-course-webinar-series/
#telehealth #telemedicine #startups #healthcare #healthIT #physicians #hospitals #pharma #prescribing #healthtech #healthlaw
Researchmoz | Dermatology Partnering Terms And AgreementsQYResearchReports
http://www.researchmoz.us/dermatology-partnering-terms-and-agreements-report.html
Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right tlicense the licensors dermatology technology. These deals tend tbe multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest dermatology deals and contracts announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight intthe negotiation process in terms of what you can expect tachieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases dnot.
Licensing partnering terms and agreements in pharma, biotech and diagnosticsKate Cleverley
“The Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics” provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Research aarkstore enterprise sexual health partnering terms and agreements
1. ResearchAarkstore Enterprise Sexual Health Partnering Terms and Agreements
The Sexual Health Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the sexual health partnering deals and agreements
entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter
sexual health partnering deals. The majority of deals are discovery or development stage
whereby the licensee obtains a right or an option right to license the licensors sexual health
technology. These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical
insight into the negotiation process in terms of what you can expect to achieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are triggered – contract documents
provide this insight where press releases do not.
This report contains over 500 links to online copies of actual sexual health deals and contract
documents as submitted to the Securities Exchange Commission by companies and their
partners. Contract documents provide the answers to numerous questions about a prospective
partner’s flexibility on a wide range of important issues, many of which will have a significant
impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of sexual health dealmaking and
business activities. Chapter 1 provides an introduction to the report.
For more information please visit link:
http://www.aarkstore.com/reports/Sexual-Health-Partnering-Terms-and-Agreements-
225583.html
Neel
Aarkstore Enterprise
Phone:08149852585
Email:enquiry@aarkstore.com
URL:www.aarkstore.com
2. http://www.facebook.com/aarkstoreenterprise
http://in.linkedin.com/in/aarkstore
Biomarker Partnering Terms & Agreements
Companion Diagnostics Partnering Terms & Agreements
Bioinformatics Partnering Terms & Agreements
Personalized Medicine Partnering Terms and Agreements
Personalized Medicine Partnering Terms and Agreements
Dermatology Partnering Terms and Agreements
Cardiovascular Partnering Terms and Agreements
Obstretics Partnering 2007-2012
Musculoskeletal Partnering Agreements
Oncology Partnering Terms and Agreements
Pediatrics Partnering Terms and Agreements
Metabolic Partnering Terms and Agreements
Immunology Partnering Terms and Agreements
Genitourinary Partnering Terms and Agreements
Gastrointestinal Partnering Terms and Agreements
Dental Partnering Terms and Agreements
Central Nervous System Partnering Terms and Agreements
Sexual Health Partnering Terms and Agreements
Mucositis Partnering 2007-2012
Oral Health Partnering 2007-2012
AIDS Partnering 2007-2012
Allergy Partnering 2007-2012
Systemic Lupus Partnering 2007-2012
Inflammatory Partnering 2007-2012
Gynecology Partnering Terms and Agreements
Respiratory Partnering Terms and Agreements